Day: April 1, 2025

The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ All dollar amounts are stated in United States (U.S.) Dollars unless otherwise noted. VANCOUVER, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) is pleased to announce it has entered into a definitive share purchase agreement (the “Agreement”) to acquire all of the outstanding shares of Compañia Minera Kolpa S.A. (“Minera Kolpa”), and its main asset, the Huachocolpa Uno Mine (“Kolpa”), from its shareholders, which are affiliates of Arias Resource Capital Management and Grupo Raffo (collectively, the “Shareholders”), in exchange for total consideration of $145 million. The total consideration will be comprised of $80 million...

ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or the “Company”), a world leader in recombinant spider silk technology, today announced that it has secured four registered trademarks for its SpydaSilk® brand. These trademarks represent a key milestone in the Company’s strategy to commercialize its revolutionary spider silk technology and position SpydaSilk® as a premium apparel brand.The newly secured trademarks provide legal protection for the SpydaSilk® brand as Kraig Labs continues to expand its production capabilities and moves toward commercialization. SpydaSilk® is a Singapore based joint venture company that Kraig Labs co-founded in 2021 to create a direct-to-consumer marketing channel for its spider silk materials. The Company...

MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:A fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum at 10:00 a.m. ET on Wednesday, April 9, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/stifel99/celc/2065375; and A fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/needham146/celc/2212811.Alternatively, the live webcasts will...

ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 12:45 p.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months. About Clearside Biomedical, Inc. Clearside Biomedical, Inc. is a biopharmaceutical company...

Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China Wilmington, Del., April 01, 2025 (GLOBE NEWSWIRE) — Ashland has completed a 10-million-dollar expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil and will celebrate the occasion with a ribbon-cutting ceremony on April 4, 2025. The investment significantly expands Ashland’s pharmaceutical footprint in the region and capabilities to meet increasing market demand for coated tablets in Latin America and Brazil. Between 2019 and 2023 the consumption of coated tablets in Latin America had an average growth of 4.3 percent per year, while Brazil has reached growth of 5.7 percent per year+.  The investment also includes the modernization of equipment for microbial...

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) plans to release its first quarter 2025 financial results after market close on Wednesday, April 30, 2025. Senior management will host a conference call on Thursday, May 1, 2025 at 11:00 am ET to discuss the results. The Company will hold its 2025 Annual General and Special Meeting of Shareholders (the “Annual Meeting”) on Thursday, May 29, 2025. Notice of First Quarter 2025 Results and Conference CallParticipants may join the conference call via webcast or through the following dial-in numbers:     Toronto and International:   (416) 406-0743Toll free (Canada and the United States):   (800) 898-3989Participant passcode:   7495836#Webcast:   www.alamosgold.comA playback will be available until June 1,...

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema. The U.S. Food and Drug Administration (FDA) previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in March 2022. “Today, we are diligently executing our phase 3 development program evaluating the efficacy and safety of deucrictibant in HAE. By granting...